Results from the DUAL V trial, which compared insulin degludec/liraglutide with insulin glargine up-titration for patients with uncontrolled Type 2 Diabetes, were published on 2016-01-01 in JAMA. The study evaluated the effect of these treatments on glycated hemoglobin levels and their overall safety profile.
Background
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The DUAL V trial investigated a combination of insulin degludec (a long-acting insulin) and liraglutide against insulin glargine, another long-acting insulin, for the management of Type 2 Diabetes. This comparison aimed to provide insights into optimizing glycemic control in patients whose diabetes was not adequately managed by existing therapies.
Trial design
The DUAL V trial was a comparative study evaluating treatment strategies for patients with uncontrolled Type 2 Diabetes. The study compared the effect of insulin degludec/liraglutide against insulin glargine up-titration. The primary focus was on changes in glycated hemoglobin levels, alongside an assessment of safety in the study population.
Key results
The DUAL V trial's publication detailed the comparative findings regarding the effect of insulin degludec/liraglutide versus insulin glargine up-titration on glycated hemoglobin levels. The study also presented data on the safety profiles associated with each treatment regimen in patients with uncontrolled Type 2 Diabetes.
What this means
The publication of the DUAL V trial provides clinicians with comparative data on two distinct insulin-based treatment strategies for patients with uncontrolled Type 2 Diabetes. By evaluating both glycated hemoglobin levels and safety, the study contributes to understanding the relative benefits and risks of insulin degludec/liraglutide versus insulin glargine up-titration in this patient population. This information supports informed decision-making in personalizing diabetes management.
Source
The results of the DUAL V trial were published on 2016-01-01 in JAMA, as indexed by PubMed. The full publication can be accessed via pubmed.ncbi.nlm.nih.gov.